Pfizer plans no further investment in Russia, says CEO Albert Bourla

France Nouvelles Nouvelles

Pfizer plans no further investment in Russia, says CEO Albert Bourla
France Dernières Nouvelles,France Actualités
  • 📰 CBSNews
  • ⏱ Reading Time:
  • 13 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 8%
  • Publisher: 68%

Bourla said the company's exposure in Russia is limited, and that any financial fallout from the war will be 'very minimal' to Pfizer's bottom line.

says his company does not have plans to invest further in Russia, as that nation's invasion of Ukraine is about to enter its third week. moderator Margaret Brennan that Pfizer is not cutting ties with Russia entirely, and noted that while the company makes"some medicines in Russia for Russia," the company does not export from Russia. screen shot

Bourla pointed out that trade restrictions often exempt lifesaving pharmaceuticals for humanitarian reasons. "How can you say I'm not going to send the cancer medicines to Russians because of what they did," Bourla said.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

CBSNews /  🏆 87. in US

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Jared Kushner key to doubling vaccines for US: Pfizer CEOJared Kushner key to doubling vaccines for US: Pfizer CEOFormer White House adviser and top Trump negotiator Jared Kushner played the key role in doubling the number of Pfizer vaccine doses the firm initially set aside for Americans, a move that may have helped slow the coronavirus spread much faster, according to a new book.
Lire la suite »

Most Side Effects From Pfizer, Moderna Covid Shots Are Mild And Short-Lived, Major Study FindsMost Side Effects From Pfizer, Moderna Covid Shots Are Mild And Short-Lived, Major Study FindsI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Lire la suite »

Pfizer Starts Testing Its Covid-19 Pill in ChildrenPfizer Starts Testing Its Covid-19 Pill in ChildrenPfizer expects results from its study of the Covid-19 drug Paxlovid in high-risk children by the end of the year
Lire la suite »

Phase 2, 3 trial for Pfizer pill for COVID begins in children ages 6 to 17Phase 2, 3 trial for Pfizer pill for COVID begins in children ages 6 to 17'There is a significant unmet need for outpatient treatments that can be taken by children and adolescents to help prevent progression to severe illness, including hospitalization or death.'
Lire la suite »

Phase 2, 3 trial for Pfizer pill for COVID begins in children ages 6 to 17Phase 2, 3 trial for Pfizer pill for COVID begins in children ages 6 to 17'There is a significant unmet need for outpatient treatments that can be taken by children and adolescents to help prevent progression to severe illness, including hospitalization or death.'
Lire la suite »

Phase 2, 3 trial for Pfizer pill for COVID begins in children ages 6 to 17Phase 2, 3 trial for Pfizer pill for COVID begins in children ages 6 to 17'There is a significant unmet need for outpatient treatments that can be taken by children and adolescents to help prevent progression to severe illness, including hospitalization or death.'
Lire la suite »



Render Time: 2025-04-25 18:02:08